• Trial of the Week: PROWESS-SHOCK

  • Jun 21 2024
  • Duración: 1 h
  • Podcast

Trial of the Week: PROWESS-SHOCK Por arte de portada

Trial of the Week: PROWESS-SHOCK

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Trial of the Week: PROWESS-SHOCK Special Guest: Paul Szumita, PharmD, FCCM, FASHP, BCCCP, BCPS @paulszumita 03:30 – Background studies/Setting the scene 30:25 – PROWESS-SHOCK discussion/Where are we now Paul Szumita joins to highlight a June Trial of the Week “Drotrecogin alfa (activated) in adults with septic shock” published in the New England Journal of Medicine in 2012. To fully understand the discussion regarding drotrecogin alfa, Paul and I review the mechanism of action and its proposed action in the treatment of sepsis. Then we review earlier studies and the controversy behind the FDA approval process. Finally, we go into detail on what Clinical Pharmacists were tasked with doing at the time based on treatment protocols or hospital restrictions. Then we dive into the Trial of the Week, discussing the study design and results. What was the mood in ICUs and Pharmacy Departments after this publication? How much did our sepsis care improve from PROWESS to PROWESS-SHOCK? What lessons did we learn with the Xigris FDA approval process? Is there a patient population that could still benefit from drotrecogin alfa treatment? Plus, trial fun facts, issues with calculating APACHE II scores, and so much more. Reference list: https://pharmacytodose.com/wp-content/uploads/2024/06/prowess-shock-trial-of-the-week-references.pdf PharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices
    Más Menos
activate_primeday_promo_in_buybox_DT
Enfermedades Físicas Hygiene & Healthy Living
Más Menos

Lo que los oyentes dicen sobre Trial of the Week: PROWESS-SHOCK

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles